Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer

Abstract

Human epidermal growth factor receptor 2 (HER2) is a major drug target and clinical biomarker in breast cancer treatment. Targeting HER2 gene amplification is one of the greatest successes in oncology, resulting in the use of a wide array of HER2-directed agents in the clinic. The discovery of HER2-activating mutations as novel therapeutic targets in breast and other cancers marked a significant advance in the field, which led to the metastatic breast and other solid tumor trials MutHER (NCT01670877), SUMMIT (NCT01953926), and one arm of plasmaMATCH (NCT03182634). These trials reported initial clinical benefit followed by eventual relapse ascribed to either primary or acquired resistance. These resistance mechanisms are mediated by additional secondary genomic alterations within HER2 itself and via hyperactivation of oncogenic signaling within the downstream signaling axis.

Keywords

Neratinib / HER2 / ERBB2 / estrogen receptor / mutation

References

[1] Kunte S,Montero AJ.Novel HER2-targeted therapies for HER2-positive metastatic breast cancer.Cancer2020;126:4278-88

[2] Bose R,Searleman AC.Activating HER2 mutations in HER2 gene amplification negative breast cancer.Cancer Discov2013;3:224-37 PMCID:PMC3570596

[3] Shimamura T,Minami Y.Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.Cancer Res2006;66:6487-91

[4] Hyman DM,Won H.HER kinase inhibition in patients with HER2- and HER3-mutant cancers.Nature2018;554:189-94 PMCID:PMC5808581

[5] Kavuri SM,Galimi F.HER2 activating mutations are targets for colorectal cancer treatment.Cancer Discov2015;5:832-41 PMCID:PMC4527087

[6] Zabransky DJ,Cochran RL.HER2 missense mutations have distinct effects on oncogenic signaling and migration.Proc Natl Acad Sci USA2015;112:E6205-14 PMCID:PMC4653184

[7] Ma CX,Gao F.Neratinib efficacy and circulating tumor DNA detection of HER2 mutations in HER2 nonamplified metastatic breast cancer.Clin Cancer Res2017;23:5687-95 PMCID:PMC6746403

[8] Ma CX,Freedman RA.The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2-mutated, non-amplified metastatic breast cancer.Clin Cancer Res2022;28:1258-67

[9] Smyth LM,Won HH.Efficacy and determinants of response to HER kinase inhibition in HER2-mutant metastatic breast cancer.Cancer Discov2020;10:198-213 PMCID:PMC7007377

[10] Schram A,Andre F.Abstract LB-103: landscape of somatic ERBB2 mutations: findings from AACR GENIE and comparison to ongoing ERBB2 mutant basket study.Cancer Res2017;77:LB103

[11] Connell CM.Activating HER2 mutations as emerging targets in multiple solid cancers.ESMO Open2017;2:e000279 PMCID:PMC5708307

[12] Croessmann S,Kinch LN.Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer.Clin Cancer Res2019;25:277-89 PMCID:PMC6320312

[13] Razavi P,Xu G.The genomic landscape of endocrine-resistant advanced breast cancers.Cancer Cell2018;34:427-438.e6 PMCID:PMC6327853

[14] Desmedt C,Gundem G.Genomic characterization of primary invasive lobular breast cancer.J Clin Oncol2016;34:1872-81

[15] Wang T,Sheng S.HER2 somatic mutations are associated with poor survival in HER2-negative breast cancers.Cancer Sci2017;108:671-7 PMCID:PMC5406600

[16] Kurozumi S,Monteiro CJ.Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.Breast Cancer Res2020;22:85 PMCID:PMC7422515

[17] Nayar U,Kapstad C.Acquired HER2 mutations in ER⁺ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.Nat Genet2019;51:207-16

[18] Rabindran SK,Rosfjord EC.Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.Cancer Res2004;64:3958-65

[19] Martin M,Ejlertsen B.Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2017;18:1688-700

[20] Saura C,Feng YH.NALA InvestigatorsNeratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial.J Clin Oncol2020;38:3138-49 PMCID:PMC7499616

[21] Turner NC,Kilburn LS.Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.Lancet Oncol2020;21:1296-308 PMCID:PMC7599319

[22] Sudhan DR,Won H.Hyperactivation of TORC1 drives resistance to the pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers.Cancer Cell2020;37:183-199.e5 PMCID:PMC7301608

[23] Hanker AB,Sheehan JH.An acquired HER2^T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer.Cancer Discov2017;7:575-85 PMCID:PMC5457707

[24] Smyth L,Saura C.Abstract PD3-06: neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer: updated results from the phase 2 SUMMIT trial.Cancer Res2019;79(4 Suppl):PD3-06

[25] Collier TS,Monsey J,Sept D.Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface.J Biol Chem2013;288:25254-64 PMCID:PMC3757188

[26] Hanker AB,Meiler J.Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.Cancer Cell2021;39:1099-1114.e8 PMCID:PMC8355076

[27] Cocco E,Razavi P.Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).Sci Signal2018;11:eaat9773 PMCID:PMC6498841

[28] Xu X,Burke KA.HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2⁺ breast cancer.Clin Cancer Res2017;23:5123-34 PMCID:PMC5762201

[29] Kingston B,Bye H.Genomic profile of advanced breast cancer in circulating tumour DNA.Nat Commun2021;12:4479

[30] Jhaveri K,Guerrero-Zotano A.Abstract PD1-05: latest findings from the breast cancer cohort in SUMMIT - a phase 2 ‘basket’ trial of neratinib + trastuzumab + fulvestrant for HER2 -mutant, hormone receptor-positive, metastatic breast cancer.Cancer Res2021;81:PD1-05

[31] Jhaveri K,Waisman J.Abstract GS4-10: neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial.Cancer Res2022;82:GS4-10

[32] Ivanova E,Xu M.Use of ex vivo patient-derived tumor organotypic spheroids to identify combination therapies for HER2 mutant non-small cell lung cancer.Clin Cancer Res2020;26:2393-403 PMCID:PMC7967092

[33] Zhang Y,Liu C.Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.Cancer Lett2016;382:176-85

[34] Bose R,Primeau TM.Abstract PS4-13: irreversible inhibition of HER2 activating mutations with neratinib enhances the pre-clinical efficacy of trastuzumab emtansine and trastuzumab deruxtecan.Cancer Res2021;81:PS4-13

[35] Abraham J,Jankowitz RC.Safety and efficacy of T-DM1 plus neratinib in patients with metastatic HER2-positive breast cancer: NSABP foundation trial FB-10.J Clin Oncol2019;37:2601-9 PMCID:PMC6784849

[36] Zhao M,Evans KW.Combining neratinib with CDK4/6, mTOR, and MEK inhibitors in models of HER2-positive cancer.Clin Cancer Res2021;27:1681-94 PMCID:PMC8075007

[37] Piha-Paul SA,Hong DS.Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 mutation/amplification or HER3/4 mutation.J Clin Oncol2018;36(15 Suppl):TPS2611

[38] Chan A,Marx G.Abstract P5-18-02: final findings from the CONTROL trial of diarrheal prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer.Cancer Res2022;82(4 Suppl):P5-18